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Extracellular vesicles (EVs) are small vesicles released by cells to aid
cell–cell communication and tissue homeostasis. Human islet amy-
loid polypeptide (IAPP) is the major component of amyloid deposits
found in pancreatic islets of patients with type 2 diabetes (T2D).
IAPP is secreted in conjunction with insulin from pancreatic β cells
to regulate glucose metabolism. Here, using a combination of ana-
lytical and biophysical methods in vitro, we tested whether EVs
isolated from pancreatic islets of healthy patients and patients with
T2D modulate IAPP amyloid formation. We discovered that pancre-
atic EVs from healthy patients reduce IAPP amyloid formation by
peptide scavenging, but T2D pancreatic and human serum EVs have
no effect. In accordance with these differential effects, the insulin:
C-peptide ratio and lipid composition differ between EVs from
healthy pancreas and EVs from T2D pancreas and serum. It appears
that healthy pancreatic EVs limit IAPP amyloid formation via direct
binding as a tissue-specific control mechanism.
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Type 2 diabetes (T2D) is becoming increasingly common world-wide, due in part to the rise in obesity (1). Like many neu-
rodegenerative disorders, such as Parkinson’s and Alzheimer’s
diseases, as well as various systemic amyloidosis conditions, T2D is
a protein-misfolding disease involving aberrant amyloid fiber for-
mation (2). The primary pathological characteristic of T2D is islet
amyloid of the hormone amylin, also known as islet amyloid
polypeptide (IAPP), in pancreatic β cells (3–6). The process of
islet amyloid formation (7–9) leads to pancreatic β-cell dysfunc-
tion, followed by cell death. In T2D, compromised β-cell function
causes a gradual loss of β-cell mass, which impairs insulin (INS)
secretion (10, 11). IAPP is cosecreted with INS after enzymatic
maturation of prohormones pro-IAPP and proinsulin in secretory
granules (12). IAPP and INS have roles in controlling gastric
emptying and glucose homeostasis and in suppressing glucagon
release. Although not understood on a mechanistic level, impair-
ment of prohormone processing is thought to play a role in the
initiation and progression of T2D (13, 14).
Virtually all cells in an organism secrete extracellular vesicles
(EVs), a heterogeneous population of membrane-enclosed vesicles
that transport and deliver payloads of proteins and nucleic acids to
recipient cells (15, 16). The protein, nucleic acid, and lipid con-
tents of EVs vary depending on the source cell, and the contents of
EVs from different cell types have been characterized (www.
microvesicles.org; www.exocarta.org). In recent years, research
into EVs has expanded dramatically with a major focus on exo-
somes, defined by their size and the presence of various protein
and nucleic acid markers (17). Exosomes are ∼100 nm in diameter,
of endosomal origin, and facilitate intercellular communication.
Exosomes have been shown to regulate many pathophysiological
processes, including immune response, inflammation, and in-
fection (18, 19), but their roles in metabolic diseases have not been
well explored (20). Pancreatic islets and β cells also secrete EVs,
which have been found to regulate local and systemic responses to
β-cell stress (21) and to transfer cargo to, for example, phagocytes
(22). Moreover, EVs from pancreatic cancer cells appear to play a
role in autoimmunity (23) and β-cell dysfunction (24), and to
possibly act as disease biomarkers (18, 19). Analysis of the mRNA
content of EVs secreted from human pancreatic islets has sug-
gested a putative role in β-cell–endothelium cross-talk and neo-
angiogenesis (25). It may be speculated that EVs derived from
pancreatic islets of patients with TD2 (compared with EVs from
islets of healthy donors) may reflect phenotypic changes occurring
in the β cells during disease development.
Even with a few recent reports, the roles of EVs, such as
exosomes, in amyloid diseases remain mostly unexplored. Exo-
somes from neuroblastoma cells were found to accelerate amy-
loid formation of the Parkinson’s disease protein α-synuclein
in vitro via a process that depends on certain ganglioside lipids in
the neuronal exosomes (26). Neuron-derived exosomes have
been found to promote amyloid β peptides to form nontoxic
amyloids, which are internalized by microglia and then trans-
ported to lysosomes for degradation (27). EVs also have been
shown to transport amyloidogenic proteins and amyloid fiber
seeds or oligomers from cell to cell, potentially causing a prion-
like spread of disease (18, 19, 28). Cerebrospinal fluid exosomes
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from patients with Parkinson’s disease have been found to con-
tain α-synuclein species that readily induce aggregation of
α-synculein in a reporter cell line (29). Investigations of the
putative effects on IAPP amyloid formation by EVs secreted
from pancreatic islets in the context of T2D are lacking, how-
ever. Since IAPP amyloid formation is affected by synthetic lipid
vesicles in vitro (8, 30–32), EVs may be predicted to have effects
as well. To begin to address this question, we isolated and
characterized EVs from pancreatic islets of healthy patients and
patients with T2D, and investigated the effects of these EVs on
IAPP amyloid formation in vitro.
Results and Discussion
Characterization of Human Islet EVs.EVs were collected from cultures
of human pancreatic islets from healthy patients and patients with
T2D, which contained a mean of 1,500 ± 433 and 1,900 ± 630
islets/mL, respectively (SI Appendix, Table S1). In addition to EVs
from healthy and diabetic pancreatic islets, we also included EVs
isolated from human serum as control EVs. Analysis of total pro-
tein content (Fig. 1A) and total particle content (Fig. 1B) revealed
similar concentrations in all three EV samples (i.e., ∼5 mg/mL
protein; 5–10 nM EVs). The size distribution of the EVs was
characterized by nanoparticle tracking analysis (NTA) (Fig. 1C),
which showed the control serum EVs to be the largest (∼105 nm)
and the healthy pancreas EVs to be the smallest (∼95 nm), but
overall all EVs showed a size distribution of ∼100 nm in diameter,
a value typically associated with exosomes (17). The measured ζ
potentials for the EVs were all negative and did not vary among the
three types (Fig. 1D). The values obtained were in the same range
as those for small unilamellar vesicles made with anionic lipids (26).
A comparison of ζ potentials between pancreatic EVs and exo-
somes from neuronal cells (26) showed that pancreatic EVs are less
negatively charged (−7 mV vs. −16 mV).
To get an idea about the cargo of the EVs, we analyzed pro-
tein content by ELISA. In related work, we have established that
the pancreatic EVs contain many typical markers of exosomes,
probed at both mRNA and protein levels. Here, we quantified
the content of INS, C-peptide (C-PEP; the C-terminal part of the
pro-INS peptide, cleaved off when mature INS is produced; ref.
12), and IAPP in the three types of EVs studied (Fig. 1 D–F). We
found the EVs from healthy islets to have approximately fivefold
less INS than C-PEP, whereas for T2D EVs and serum EVs, the
amounts of INS and C-PEP were roughly equal. Notably, the
absolute amount of C-PEP was lower in T2D and serum-derived
Fig. 1. Human pancreatic islet EV characterization. EVs were isolated from cultures of 10 mL of nondiabetic islets donors (h-Islet-EVs), islets from diabetic
donors (h-T2D-EVs), and human serum from culture medium (h-Ctr-EVs). EVs were characterized by total protein concentration (A), particle concentration
(B), size distribution (C), ζ potential (D), and human pancreatic hormones INS (E), C-PEP (F), and IAPP (G) as measured by ELISA. *, **, and *** represent
statistical significance: *P < 0.05; **P < 0.01; ***P < 0.001.
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EVs than in EVs from healthy islets, but IAPP amounts were
similar in all three EV types. Less INS than C-PEP matches with
the lower stability of INS (vs. C-PEP) in vivo, resulting in fivefold
less INS compared with C-PEP in systemic circulation under
normal conditions (33). Because C-PEP appears to be the best
indicator of INS production, the lower levels of C-PEP in T2D
EVs may reflect lower INS production. Nonetheless, how the
peptide levels inside EVs relate to the amounts circulating in the
body is not clear. Despite the lack of a molecular explanation,
these results demonstrate divergent C-PEP content between
healthy and T2D pancreatic EVs.
EV Effects on IAPP Amyloid Formation. We next assessed IAPP
amyloid formation as a function of EV additions. For this, we
used thioflavin T (ThT) fluorescence to monitor amyloid for-
mation, as is commonly used in in vitro amyloid experiments (34,
35). IAPP alone is aggregation-prone and forms amyloids within
5–10 min under the conditions used here (Fig. 2A). When EVs
from healthy islets were added, a concentration-dependent (us-
ing EV protein content as the measure, which is proportional to
the number of EVs) decrease in ThT fluorescence was detected
(Fig. 2A). Analysis of fluorescence at 10 min as a measure of
reaction extent demonstrated significantly reduced amyloid for-
mation at the highest EV concentration used, 25 μg/mL of EV
protein (corresponding to ∼0.05 nM EVs) (Fig. 2B).
To assess whether the EVs themselves were responsible for the
retarding effects on IAPP amyloid formation, we filtered the EVs
and tested the EV-free solution in IAPP aggregation reactions (SI
Appendix, Fig. S1A). No effect of the EV-free solution on IAPP
amyloid formation was detected, implying that it is indeed the EVs
(specific lipids or membrane-protruding proteins) that mediate
the effect. As a control, we added BSA in the same amount as the
EV protein content (25 μg/mL), and found no effect on IAPP
amyloid formation (SI Appendix, Fig. S1A). We note that EVs
alone had no effect on ThT fluorescence (SI Appendix, Fig. S1B),
and when EVs were added to preaggregated IAPP (i.e., after
a 20-min incubation), no reduction of the ThT intensity was
detected (SI Appendix, Fig. S1C). Thus, the EVs do not dissolve
preformed IAPP amyloid fibers.
To directly compare EVs from healthy and T2D islets as well
as human serum EVs, we added all three types to IAPP aggre-
gation experiments at a concentration of 25 μg/mL (Fig. 3A). The
ThT assay showed a significant retardation of amyloid formation
in the healthy EVs, as confirmed in Fig. 2B. TEM analysis of the
resulting products revealed that in contrast to IAPP alone, in
which typical amyloid fibers were readily observed, no amyloid
fibers were detected in IAPP mixed with healthy pancreatic EVs
(Fig. 3C). Instead, some amorphous aggregates were visible in
the images that may be EVs alone or EVs with IAPP. When T2D
and serum EVs were added to IAPP aggregation reactions, no
significant effects on IAPP amyloid formation were detected
(Fig. 3B) and amyloid fibers were clearly detected by TEM (Fig.
3C), although they appeared “fuzzy,” implying that EV frag-
ments may attach to the IAPP amyloids.
To test the amyloid-reducing effect of the EVs from pancreatic
islets on another aggregation-prone polypeptide, we turned to
α-synuclein. The 140-residue α-synuclein is the amyloidogenic
protein in Parkinson’s disease and the major component of Lewy
bodies found in brains of patients with Parkinson’s disease (36–
38), but also can be found in the pancreas (39). We recently
showed that IAPP monomers and IAPP amyloid fibers can ex-
aggerate α-synuclein amyloid formation in vitro, suggesting a
possible explanation for why individuals with T2D are prone to
Parkinson’s disease (40). Interestingly, as probed by ThT fluo-
rescence and atomic force microscopy (AFM), EVs from both
healthy and T2D islets reduced α-synuclein amyloid formation
when added at the same EV:protein ratio as in the IAPP experi-
ments (SI Appendix, Fig. S2). This is a reasonable result, given that
several types of negatively charged synthetic lipid vesicles can bind
α-synuclein and modulate amyloid formation (41).
Mechanistic Insights into EV-Mediated IAPP Amyloid Inhibition. To
address how healthy pancreatic EVs inhibit IAPP amyloid for-
mation, we probed the mixtures using size exclusion chroma-
tography (SEC). Freshly dissolved IAPP elutes as a monomer
(Fig. 4A), whereas EVs are large enough to elute in the void of
the SEC column but are not filtered away in the 0.2-μm pre-
column filter (Fig. 4B). AFM of the EV fraction showed the
presence of nanosized vesicles (Fig. 4B), in accordance with the
NTA data. When IAPP and EVs were freshly mixed together
and immediately eluted, no reaction was apparent, with the
elution profile matching the sum of the individual samples de-
scribed above (Fig. 4C). Incubation of IAPP resulted in amyloid
fibers, which were filtered away before injection into the column,
with no absorption at 280 nm detected on SEC (Fig. 4D).
However, for an incubated mixture of IAPP and healthy islet
EVs that showed no increase in ThT fluorescence or amyloid
fibers by TEM, no monomeric IAPP was detected by SEC, and
absorption of the EVs in the void was reduced (Fig. 4D, arrow).
This suggests that IAPP binds to the EVs, resulting in larger
particles, some of which are filtered away before SEC analysis, as
well as the absence of monomeric IAPP. This result is not direct
proof of an IAPP–EV interaction, however. Nonetheless, in
agreement with the conclusion based on the SEC analysis, AFM
showed that the EVs appeared larger in the presence of IAPP
(Fig. 4E). The larger EVs can be explained either by IAPP-
induced fusion of several EVs or by surface binding of many
IAPP peptides per EV.
We also analyzed the lipid composition of the EVs using the
HPLC-charged aerosol detection (CAD) technique (Fig. 5
and SI Appendix, Fig. S4). Six classes of lipids were detected
and could be quantified: steryl ester (SE), triacylglycerol
(TAG), cholesterol (CH), phosphatidylethanolamine (PE),
sphingomyelin (SM), and phosphatidylcholine (PC). We also
searched for free fatty acids, cardiolipin, phosphatic acid,
Fig. 2. Concentration-dependent effect of h-Islet-EVs on h-IAPP aggre-
gation. (A) ThT fluorescence assay over time (min). (B) Mean intensity at
10 min of incubation. *Statistical significance compared with 0 μg/mL EVs:
P < 0.05.








phosphatidylserine, and phosphatidylinositol, but did not detect
these molecules in our samples. A comparison of the lipid con-
tents in the three different EV samples showed different lipid
profiles in serum EVs and pancreatic EVs (Fig. 5A), as could be
expected. Although no significant differences between healthy and
T2D pancreatic EVs were found on two-way ANOVA (SI Ap-
pendix, Fig. S3), this analysis suggested that healthy EVs have
slightly higher CH, PC, and SM levels (at the expense of TAG and
PE) compared with T2D EVs (Fig. 5 and SI Appendix, Fig. S3).
CH and SM are important membrane components affecting
membrane fluidity and lipid raft formation (42), and it has been
reported that the presence of SM in PC-based liposomes slows
(43), and the addition of CH to synthetic lipid membranes inhibits,
IAPP amyloid formation (43, 44). These results support the idea
that SM and/or CH in healthy pancreatic EVs may help mediate
the inhibitory effect on IAPP amyloid formation. We also found a
higher lipid:protein ratio in healthy pancreatic EVs compared with
T2D EVs, implying more exposed lipid surfaces in the former
(Fig. 5B). To pinpoint how healthy EVs bind IAPP on a molecular
level, further studies using lipid vesicles of strategic compositions,
along with identification of proteins exposed on the EV mem-
brane surfaces, are needed.
Conclusions
Several studies have reported accelerated IAPP amyloid forma-
tion in the presence of synthetic vesicles rich in negatively charged
lipids. Thus, our finding of healthy pancreatic EVs limiting IAPP
amyloid formation is surprising at first glance. However, recent
work has shown that IAPP amyloid formation is strongly reduced
by the extracellular environment and by plasma membranes of
Fig. 3. Aggregation of IAPP in the presence of different EV populations. (A) ThT fluorescence assay over time (min). (B) mean ThT intensity at 10 min of
incubation. **Statistical significance compared with 0 μg/mL EVs: P < 0.01. (C) TEM imaging of typical fibrils formed. (Scale bar: 100 nm.) The arrow points to
an intact EV.
Fig. 4. Assessment of IAPP interaction with healthy pancreatic EVs by SEC and AFM. (A) SEC of freshly eluted IAPP (monomers). (B) SEC of EVs (elutes in the
void), with AFM imaging of the indicated fraction. (C) SEC of a mixture of IAPP and EVs without incubation (elutes as monomeric IAPP and EVs in the void, i.e.,
as a combination of the traces in A and B). (D) SEC of IAPP (which forms amyloids and is filtered away before SEC injection) and a mixture of IAPP and EVs
preincubated for 20 min at 37 °C before SEC analysis. The eluate contains no monomeric IAPP; instead, absorption of EVs in void is decreased, which may be
explained by the formation of larger particles that are partially filtered away before SEC. The arrow points to reduced absorption of EVs after incubation with
IAPP. (E) AFM image of an incubated mixture of IAPP and EVs (larger particles than in the AFM image in B).
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pancreatic β cells (45). The authors speculated about the presence
of particular lipids or proteins in the plasma membranes and/or
secreted molecules that mediated this effect. Based on our present
results, we propose that secreted EVs from the pancreatic islets
used in that study might have mediated the observed inhibitory
effects. Of note, we found that the amyloid-reducing effect origi-
nated from the EVs themselves, not from any EV-secreted mol-
ecule or soluble component in the media, and involved IAPP
surface binding and/or internalization. The next step is to identify
the molecular mechanisms underlying IAPP amyloid retardation
by healthy pancreatic EVs, including the EV lipids and/or proteins
that are the key players.
Materials and Methods
Human Pancreatic Islets. Human primary islets isolated from donor pancreases
obtained from deceased individuals, with research consent from organ
procurement organizations, were purchased from Prodo Laboratories. The
use and storage of human islets were conducted in compliance with the
Declaration of Helsinki and International Council for Harmonisation of
Technical Requirements for Pharmaceuticals for Human Use Good Clinical
Practice guidelines, and was approved by an independent Regional Ethics
Committee. Islets were transported in PIM(S) medium (Prodo Laboratories)
and then transferred to fresh PIM(S) medium for overnight recovery.
EV Isolation. Human pancreatic islet-derived EVs were isolated from fresh
pancreatic islet-conditioned media. Donor information is provided in SI
Appendix, Table S1. Male and female donors were used for the isolation of
healthy EVs; only female donors were available for the isolation of T2D-
derived EVs. Conditioned medium isolated after 24 h of culture was used
for EV isolation. The conditioned medium was freshly centrifuged at 200 × g
for 10 min, then at 2,000 × g for 10 min, and finally at 4,000 × g for 60 min.
The supernatant was filtered through a 0.45-μm filter and incubated with
ExoQuick-TC reagent (System Biosciences) following the manufacturer’s in-
structions. EVs were then resuspended in PBS and stored at −80 °C in small
aliquots. PIM(S) medium was used to extract EVs corresponding to the hu-
man serum fraction for use as control EVs (h-Ctr-EV). Islets derived from T2D
donors were used to isolate h-T2D-EVs, and islets derived from healthy,
nondiabetic donors were used to isolate h-islet-EVs.
EV Characterization. EVs were quantified in terms of total protein and particle
concentrations. Total protein content was measured using the Pierce BCA
Protein Assay Kit (23225; Thermo Fisher Scientific). Particle concentration and
size distribution were measured by NTA using a Nanosight LM10 instrument
(Malvern Instruments). EVs were diluted in PBS to fit into the resolution
window of measurement suggested by the instrument manufacturer.
Nanosight NTA 3.1 software was used to capture and analyze the particles.
The ζ potential was measured by dynamic light scattering at 25 °C in TBS
(Zetasizer Nano ZS; Malvern Instruments). The pancreatic hormones INS (10-
1131-01; Mercodia), C-PEP (10-1141-01; Mercodia), and IAPP (LS-F9686;
LifeSpan BioSciences) were quantified by ultrasensitive ELISA following the
manufacturer’s instructions.
Proteins/Peptides. IAPP, obtained from Calbiochem (05-23-2540), was treated
with hexafluoroisopropanol (105228; Sigma-Aldrich) before use to dissolve
any preexisting aggregates. Purification of α-synuclein was done as described
previously (46). Before use, the protein was freeze-dried and dissolved in the
appropriate buffer, followed by filtration through a 0.2-μm filter.
Amyloid Formation Assay. IAPP amyloid formation was monitored in a 1-cm
cuvette using a Cary Eclipse spectrophotometer (with a magnetic stirrer bar).
IAPP aggregation was initiated by pipetting IAPP (2.5 mM stock in hexa-
fluoroisopropanol) into a reaction buffer composed of 10 μM ThT (T3516;
Sigma-Aldrich) in TBS (0.05 M Tris·HCl buffer pH 7.6 with 0.15 M NaCl; 93318,
Sigma-Aldrich) for a final concentration of 4 μM. The fluorescence signal was
recorded every 30 s at 37 °C. α-synuclein amyloid formation reactions were
conducted in a plate reader (FLUOstar Optima; BMG Labtech) in TBS buffer
in the presence of 20 μM ThT at 37 °C with agitation and a 2-mm glass bead
in each well for a final concentration of 70 μM. Samples were typically in-
cubated for 80 h, and fluorescence was measured every 20 min. For both
protein plate reader and cuvette experiments, ThT was excited at 440 nm,
and emission was recorded at 480 nm. EV supplementation was dosed in μg/mL
of total protein and freshly incubated with the peptides. EV-free solution was
used as control, using an Amicon Ultra-15 centrifugal filter unit with a mem-
brane of nominal molecular weight limit of 100 kDa. BSA (Sigma-Aldrich)
served as a protein control.
TEM. For TEM analysis, 10-μL samples from the fibrillation studies were ap-
plied to Formvar-coated 200-mesh size copper grids, incubated for 5 min,
washed with Milli-Q water, and stained with 1% uranyl acetate. The grids
were examined with a Zeiss LEO 912 Omega transmission electron micro-
scope operating at 120 kV, and images were captured by an Olympus Veleta
CCD camera.
SEC. Freshly mixed and incubated samples of 10 μM IAPP with or without
62.5 μg/mL EVs (same ratio as used for the aggregations) were loaded on a
Superdex 75 10/300 GL column connected to a Äkta Purifier chromatography
system (GE Healthcare) using TBS buffer as eluent and operated at 10 °C.
Elution was followed by measurement of absorbance at 280 nm, and 1-mL
fractions were collected for AFM analysis.
AFM. Aggregated samples were diluted in Milli-Q water (10–20 times) and
deposited on freshly cleaved mica. After 10 min, the mica was rinsed with
filtered Milli-Q water and dried under a gentle nitrogen stream. Images were
recorded on an NTEGRA Prima setup (NT-MDT) using a gold-coated single-
crystal silicon cantilever (NSG01, spring constant of ∼5.1 N/m; NT-MDT) and a
resonance frequency of ∼180 kHz. The 512-pixel images were acquired at a
0.5-Hz scan rate. Images were analyzed using WSxM 5.0 software (47).
Lipid Analysis. Each sample was extracted with a chloroform methanol
mixture (2:1, vol/vol). The samples were shaken vigorously and incubated
for 20 min at 4 °C. After incubation, water was added, followed by shaking
and incubation for 10 min at 4 °C. Phase separation was achieved by
centrifugation at 8,000 × g for 5 min. The organic layer was recovered, and
the aqueous layer was re-extracted with a mixture of chloroform and
methanol (2:1, vol/vol), shaken vigorously, and centrifuged at 8,000 × g for
5 min. The organic layers were combined, evaporated to dryness under a
steam of nitrogen, and reconstituted into a chloroform methanol mix
(1:1). The samples were analyzed using a HPLC-CAD system as described
previously (48).
Statistical Analysis.Aminimum of three independent islet donors were used for
the different experiments, with a minimum of two technical replicates per
Fig. 5. EV lipid identification. (A) Relative mass percentage of the six identified lipid classes found in h-Islet-EVs, h-T2D-EVs, and h-Ctr-EVs, with the total lipid
mass detected for each sample set to 100%. (B) Ratio of total lipid content to total protein content for each EV population. *Statistical significance: P < 0.05.








condition and assay, with the exception of the mass spectrometry analysis, for
which samples from one donor per condition was used. Data were statistically
analyzed using GraphPad Prism version 6.01. The results were analyzed for
normal distribution. Parametric or nonparametric methods were used to assess
variances in the data depending on the data normality. Automatic correction
for outliers was performed using the ROUT method (Q = 1%). The statistical
significance of calculated P values is defined in SI Appendix, Table S2; P values
of ≤0.05 were considered statistically significant in the analysis of the results.
Box-and-whisker plot graphs were used to show the distribution of the ob-
served data variation (displayed as minimum to maximum value together with
distribution around the median, i.e., upper and lower quartiles).
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